Clinical trials referenced in this document:
Documents that mention this clinical trial
Funding for this research was provided by:
National Key Research and Development Program of China (2016YFC0900901)
National Key Research and Development Program of China (2016YFC1301002, 2018YFC1312501, 2020YFC2004803)
National Key Research and Development Program of China (2017YFC0908803)
Received: 10 November 2020
Accepted: 9 March 2021
First Online: 19 March 2021
: The study was approved by the Ethics Committee on Human Research of Beijing Anzhen Hospital, the Capital Medical University. All participants provided written informed consent. Name of the ethics committee: Ethics Committee of Beijing Anzhen Hospital. Reference number: D11110700300000.
: Not applicable.
: Chang-sheng Ma has received honoraria from Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Boehringer-Ingelheim, and Bayer for giving lectures. Jian-zeng Dong has received honoraria from Johnson & Johnson for giving lectures. The rest of the authors have declared no conflict of interest.